	SEP 2 0 2001 2	(
Л PTO-14 4 9	TRADEMARKE	

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

FORM Patent and Trademark Office

U.S. Dept. of Commerce

Serial No. Atty Docket No. 09/754,998 P0941C1D1C1 Applicant Rinderknecht et al. Group Filing Date

1644

04 Jan 2001

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							2 P
Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
J.	52	WO 95/22389 /	24.08.95	PCT			Transpon No 2001
				·			
			·				
:							
Examine	r		1	T F	Date Considered SU		

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	<u>'</u>								
FORM PTO-1449				U.S. Dept. of Commerce	· · · · · · · · · · · · · · · · · · ·		Serial No. To Be'A Gigne		
				Patent and Trademark Office	ļ			A A Signed	
LICT OF DICCLOSURES CITED BY ADDITIONAL			OV ADDI ICANIT			Applicant		.o = :	
LIST OF DISCLOSURES CITED BY APPLICANT					derknecht e		- s		
(Use several sheets if necessary)			y)		,	J Date 14 Jan 2001	Group To 1	Be Assigned	
				U.S. PATENT DOCUMENTS	L	PATRICA	TO 41)	2 60	
Examiner	 						T		
Initials	1	Document Number	Date	Name		Class	Subclass	Filing Date	
LAP	* 1	4,000,098	28.12.76	Hofstee, B.		جســ			
١	* 2	5,429,746	04.07.95	Shadle et al.		1	1		
79	* 3	5,591,828	07.01.97	Bosslet, K. et al.		U	V		
My	* 4	5,648,237	15.07.97	Carter, P.			_ `		
			•	FOREIGN PATENT DOCUMEN	TS	•			
Examiner	-							Translation	
Initials		Document Number	Date	Country		Class	Subclass	Yes No	
(4.3)	* 5	AU-B-57621/90	03.01.91	AUSTRALIA		_			
iany	* 6	WO 92/12993	06.08.92	PCT		l t			
}	* 7	WO 92/22653	23.12.92	PCT					
1 1	* 8	WO 93/11161	10.06.93	PCT		1			
	* 9	WO 94/13804	23.06.94	PCT]			
\	*10	WO 94/13806	23.06.94	PCT		1 16	1		
TOP	*11	WO 97/14719	24.04.97	PCT		_		· .	
, -	l		OTHER DISCL	OSURES (Including Author, Title, Date	e Pertine	nt Pages, etc)	1 ,	
	I	Abe et al., "Puri		noclonal antibodies with light-		-	·=	by mouse	
hybridomas raised with NS-1 myelomas: application of hydrophobic interaction high-performance liquid chromatography" <u>Journal of Biochemical and Biophysical Methods</u> 27:215-227 (1993) Alfthan et al., "Purification of Labelled Antibodies by Hydrophobic Interaction Chromatography" <u>Journal of Biochemical and Biophysical Methods</u> 27:215-227 (1993)									
(*13	Chromatography 47	70(385-389):385	-389 (1989)					
1	*14			ysaccharides and Glutathione Mi ith the Use of E. coli K12" <u>Act</u>					
	-14	39(1):69-77 (1985	5)		rformance hydrophobic interaction chromatography for the determination				
	*15			performance hydrophobic interac oteins" <u>Journal of Chromatogra</u> n				determination	
	12								
	*16			f human immunoglobulin G subcla ography" Journal of Chromatogra		-	-	parison with	
7 14 2									
1	*17	Journal of Immuno	_	Immunoglobulins from Protein A- <u>s</u> 64:1-6 (1983)	-sepnaro	se CL-4B ur	ider Mild C	conditions"	
		Carter et al "H	digh level Esch	erichia coli expression and pro	duction	of a biva	ent humani	zed antibody	
	*18	fragment" Bio/Teo	-		, auction	or a siva	circ manari	Lea unclody	
		Cruse et al. Illu	strated Dictio	nary of Immunology, CRC Press,	Inc. pp	s. 18-19. 1	07-109 (19	195)	
	*19 ·			,			,		
	<u> </u>	Danielsson et al.	., "One-step pu	rification of monoclonal IgG ar	tibodie	s from mous	e ascites"	Journal of	
1	*20	Immunological Met		——————————————————————————————————————					
\ \	 	Eigenbrot et al.,	, "X-Ray Struct	ures of Fragments From Binding	and Non	binding Ver	sions of a	Humanized	
*21		Anti-CD18 Antibody: Structural Indications of the Key Role of V _H Residues 59 to 65" Proteins: Structure,							
Function, and Genetics 18:49-62 (1994) Fausnaugh et al., "Solute and Mobil Phase Contributions to Retention in Hydrophobic Interaction				ction					
TOBY	*22	Chromatography of	Proteins" J.	Chromatography 359:131-146 (198	(6)				
Examin	er	11/1/	Mh		Date Con	sidered 9/,	162		
		19/h 0	N/XI				62		
				ot citation is in conformance with MPEI			h citation		

•	

FOR	M PTO-	1449 U.S. Dept. of Commerce	Atty Docket No.	Serial No.		
Patent and Trademark Offic			P0941C1D1C1	To Be Assigned		
116	T OE DI		Applicant			
LIST OF DISCLOSURES CITED BY APPLICANT			Rinderknecht et al.			
(Use several sheets if necessary) Filing Date O4 Jan 2001 To Be As			Group To Be Assigned			
		OTHER DISCLOSURES (Including Author, Title, Date,	Pertinent Pages, etc.)			
		Fendly et al., "The Extracellular Domain of HER2/neu Is a Poten				
745	*23	Immunotherapy of Breast Cancer" <u>Journal of Biological Response I</u>				
P	*24	Gagnon et al., "Method Development and Scale-Up in the Purifical Exchange and Hydrophobic Interaction Chromatography" <u>Abstract o</u> (May 13, 1990)	f the Annual Meeting	(Abstract No. 0-4)		
	*25	Hildreth et al., "A Human Lymphocyte-associated Antigen Involved Journal of Immunology 13:202-208 (1983)				
	*26	Holliger et al., ""Diabodies": Small bivalent and bispecific and USA 90:6444-6448 (Jul 1993)	tibody fragments" <u>Pro</u>	oc. Natl. Acad. Sci.		
	*27	Hudziak et al., "p185HERZ Monoclonal Antibody Has Antiproliferat Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular & (</u>				
	*28	Inouye et al., "Fragmentation of mouse monoclonal antibodies of F(ab') ₂ fragments and the application of the fragments to immuno No. 44) pps. 1018-1019 (1993)				
	*29	Inouye et al., "One-Step Purification of F(ab') ₂ Fragments of Mo (Immunoglobulins G1 and M) by Hydrophobic Interaction HPLC" Animaspects 5:609-616 (1993)	mal Cell Technology:	Basic & Applied		
	*30	Inouye et al., "Single-step purification of F(ab') _{2µ} fragments of mouse monoclonal antibodies (immunoglobulins M) by hydrophobic interaction high-performance liquid chromatography using TSKgel Ether-5PW" Journal of Biochemical and Biophysical Methods 26:27-39 (1993)				
	*31	Johansson et al., "Purification of proteins by salt promoted adsorption chromatography" <u>Biol.</u> <u>Recombinant Microorg. Anim. Cells</u> (Oholo 34 Meeting) pps. 409-414 (1991)				
	*32	Kelley et al., "Antigen Binding thermodynamics and Antiproliferative Effects of Chimeric and Humanized anti-p185HER2 Antibody Fab Fragments" <u>Biochemistry</u> 31:5434-5441 (1992)				
	*33	Kurzban et al., "Purification of Bovine Liver Rhodanese by Low-Pexpression and Purification 2:279-384 (1991)				
	*34	Mendelson et al., "Preparation and Characterization of Polyclona Human Aromatase Cytochrome P-450 (P-450 _{AROM}), and Their Use in in Biochemistry & Biophysics 243(2):480-491 (1985)	ts Purification" <u>Arc</u>	hives of		
	*35	Morimoto et al., "Single-step purification of F(ab')2 fragments of mouse monoclonal antibodies				
	*36	Nardella et al., "Nonimmunospecific Protein-Protein Interactions to IgG Immunoadsorbents" <u>Journal of Immunology</u> 120(3):739-744 (3)	-	the Binding of IgG		
	*37	Nau et al., "The Role of Hydrophobic Interaction Chromatography in Antibody Purification - Optimization of Mobile Phase Conditions" <u>BioChromatography</u> 5(2):62-73 (1990)				
	*38	Neblock et al., "Conjugation and Evaluation of 7E3 X P4B6, a chemically Cross-Linked Bispecific F9ab')2 Antibody Which Inhibits Platelet Aggregation and Localizes Tissue Plasminogen Activator to the Platelet Surface" Bioconjugate Chem 3:126-131 (1992)				
	*39	Panka et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies" <u>Proc. Natl. Acad. Sci. USA</u> 85:3080-3084 (May 1988)				
	*40	Paulus, H., "Preparation and Biomedical Applications of Bispecia 78:118-132 (1985)				
4	*41	Pavlu et al., "Rapid Purification of Monoclonal Antibodies by Hi <u>Journal of Chromatography</u> 359:449-460 (1986)				
کھ	*42	Rea et al., "The Rapid Development of Hydrophobic Interaction Ch Monoclonal IgG _{2a} F(ab') ₂ Fragment" <u>Journal of Cellular Biochemis</u> (1993)	stry (Abstract No. X1			
Examin		1901 A 8411	ite Considered 9/6/02			
		itial if reference considered, whether or not citation is in conformance with MPEP (formance and not considered. Include copy of this form with next communication t		ition		

FORM PTO-1449 U.S. Dept. of Commerce		Atty Docket No.	Serial No.			
Patent and Trademark Office			P0941C1D1C1	To Be Assigned		
		Applicant				
LIST OF DISCLOSURES CITED BY APPLICANT		Rinderknecht et al.				
(Use several sheets if necessary)			Filing Date	Group		
04 Jan 2001 To Be						
		OTHER DISCLOSURES (Including Author, Title, Date,	•			
10	*43	Regnier, F., "High-Performance Liquid Chromatography of Biopoly	mers" <u>Science</u> 222(462	1):245-252 (1983)		
1	*44	Rodrigues et al., "Development of a Humanized Disultide-stabliz Protein for Activation of a Cephalosporin Doxorubicin Prodrug"	-			
	*45	Rodrigues et al., "Engineering Fab' Fragments for Efficient F(a Improved In Vivo Stability" The Journal of Immunology 151(12):6				
	*46	Rudikoff et al., "Single amino acid substitution altering antig Sci. USA 79:1979-1983 (1982)	en-binding specificit	y" <u>Proc. Natl. Acad.</u>		
	*47	Scopes, "Protein Purification: Principles and Practice" <u>Springe</u> Advanced Texts in Chemistry pps. 176-181 (1987)	r Advanced Texts in C	hemistry, Springer		
	*48	Shaltiel, S., "Hydrophobic Chromatography" Methods in Enzymolog	y 104:69-96 (1984)			
	*49	Williams, G., "Novel antibody reagents: production and potentia	1" <u>TIBTECH</u> 6:36-42 (1	988)		
V	*50	Young et al., "Staphylococcal Protein A Binding to the Fab Frag of Immunology 133(6):3163-3166 (Dec 1984)	ments of Mouse Monocl	onal Antibodies" <u>J.</u>		
12	*51	Zapata et al., "Engineering linear F(ab') ₂ fragments for efficient enhanced antiproliferative activity" <u>Protein Engineering</u> 8(10):		herichia coli and		
·						
		11/1 01/1				
Exami	ner	The Da	ite Considered 9/6/01			
*Exam	niner: Ini t in conf	tial if reference considered, whether or not citation is in conformance with MPEP formance and not considered. Include copy of this form with next communication to	609; draw line through citato applicant.	tion		